Ocugen, Inc. to Present at the 34th Annual ROTH Conference
March 09 2022 - 7:11AM
Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical
company focused on discovering, developing, and commercializing
gene therapies to cure blindness diseases and developing a vaccine
to save lives from COVID-19, today announces that Dr. Shankar
Musunuri, Chairman, CEO and Co-Founder of Ocugen, Inc., will be
presenting at the 34th Annual Roth Conference.
Event |
34th Annual ROTH Conference |
Date |
March 14, 2022 |
Presentation |
11:00am Pacific Time (2:00pm Eastern Time) |
Location |
Dana Point, CA |
This year’s event will consist of 1-on-1/small
group meetings, analyst-selected fireside chats, thematic industry
panels, and on-demand presentations by executive management from
approximately 400 private and public companies in a variety of
growth sectors including: Blockchain/Cryptocurrency, Business
Services, Consumer/Health & Wellness, Healthcare, Resources:
Oil & Gas/Meals & Mining, Technology & Media and
Sustainability/ESG.
To learn more and submit a registration request,
visit https://ibn.fm/ROTH2022Registration
The live audio webcast and replay will be available
in the investor relations section of the Company’s website at
https://wsw.com/webcast/roth43/ocgn/1817244. Replay of this webcast
will be available for 90 days post-presentation.
About Roth Capital Partners Roth
Capital Partners, LLC (Roth) is a relationship-driven investment
bank focused on serving emerging growth companies and their
investors. As a full-service investment bank, Roth provides capital
raising, M&A advisory, analytical research, trading,
market-making services and corporate access.
Headquartered in Newport Beach, California, Roth is
privately held and owned by its employees and maintains offices
throughout the U.S. For more information on Roth, please visit
www.roth.com.
About Ocugen, Inc.Ocugen, Inc. is
a clinical-stage biopharmaceutical company focused on discovering,
developing, and commercializing gene therapies to cure blindness
diseases and developing a vaccine to save lives from COVID-19. Our
breakthrough modifier gene therapy platform has the potential to
treat multiple retinal diseases with one drug – “one to many” and
our novel biologic product candidate aims to offer better therapy
to patients with underserved diseases such as wet age-related
macular degeneration, diabetic macular edema and diabetic
retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine
candidate for COVID-19 in the U.S. and Canadian markets. For more
information, please visit www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (“SEC”), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Ocugen Contact: Ken
InchaustiHead, Investor Relations &
CommunicationsIR@Ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024